Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

SkinHealth Systems Inc. Class A Common Stock

SKIN

SkinHealth Systems Inc is a world-wide medical aesthetics company delivering an integrated ecosystem of clinically validated solutions designed to help consumers achieve superior skin health and support the success of providers. Its brands are Hydrafacial and SkinStylus.

Last trade $13.19
Day change -$1.86 (-12.36%)
Day range $13.01 – $16.86
Volume 86,425
Market cap $98M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$98.05M
Price / earnings
—
Price / book
1.76×
Price / sales
0.34×
EV / sales
0.79×
EV / EBITDA
8.13×

Profitability

Earnings per share
-$2.81
Return on assets
-4.7%
Return on equity
-32.81%
Dividend yield
0%

Liquidity and leverage

Debt / equity
4.36×
Current ratio
2.89×
Quick ratio
2.22×
Cash ratio
1.61×

Cash flow

Price / cash flow
4.16×
Price / free cash flow
4.32×
Free cash flow
$22.69M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SKIN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$69.17M$72.11M$64.91M$82.37M$70.66M$78.19M$69.58M$83.5M
Cost of revenue$22.02M$22.78M$20.47M$29.33M$25.02M$29.08M$21M$31.15M
Gross profit$47.15M$49.34M$44.44M$53.04M$45.63M$49.11M$48.58M$52.35M
Selling, general and administrative$40.51M$44.36M$45.14M$51.2M$50.18M$50.56M$59.61M$58.28M
Research and development$1.66M$1.41M$1.1M$1.68M$1.7M$1.25M$998K$1.22M
Total operating expenses$42.17M$45.77M$46.24M$52.88M$51.88M$51.81M$60.6M$59.5M
Operating income$4.98M$3.57M-$1.8M$162K-$6.24M-$2.7M-$12.02M-$7.16M
Interest expense-$6.27M-$6.3M-$6.35M-$6.37M-$6.31M-$4.14M-$2.5M-$2.46M
Income before taxes-$108K-$1.46M-$6.81M-$4.81M-$10.65M$18.72M-$9.2M-$11.72M
Income taxes$780K$1.21M-$184K$3.3M$386K-$993K$892K-$1.39M
Net income-$888K-$2.67M-$6.63M-$8.1M-$11.03M$19.71M-$10.1M-$10.33M
Net income attributable to common shareholders-$888K-$2.67M-$6.63M-$8.1M-$11.03M$19.71M-$10.1M-$10.33M
EBITDA$10.25M$8.84M$3.54M$5.51M$2.19M$2.7M-$5.86M-$598K
Basic earnings per share-$0.14-$0.40-$1.00-$1.27-$1.74$3.20-$1.60-$1.66
Diluted earnings per share-$0.14-$0.40-$1.00-$1.07-$1.74$0.60-$1.60-$1.30

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

SkinHealth Systems Inc. (SKIN) Reports Q3 Loss, Tops Revenue Estimates

SkinHealth Systems Inc. (SKIN) reported a Q3 loss of $0.14 per share, significantly beating the consensus estimate of a $1.32 loss, representing an 89.39% earnings surprise. Revenue reached $69.2 million, surpassing estimates by 3%. However, the stock has declined 60.3% year-to-date versus the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

SkinHealth Systems Inc. (SKIN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

SkinHealth Systems Inc. reported Q3 2026 revenue of $69.2 million, down 2.1% year-over-year but beating consensus estimates by 3%. The company posted an EPS of -$0.14, a significant improvement from -$1.80 a year ago and beating estimates by 89.39%. While consumables sales grew 1.2% and Americas revenue increased 1.2%, EMEA revenue declined 11.8% and delivery systems sales fell 9.6%. The stock has underperformed the broader market, declining 6.3% over the past month.

Zacks Investment Research

SkinHealth Systems Inc. (SKIN) Soars 9.0%: Is Further Upside Left in the Stock?

SkinHealth Systems Inc. (SKIN) shares jumped 9% following completion of a 1-for-20 reverse stock split on October 14, 2026, which helped the company regain compliance with Nasdaq's minimum bid price requirement. However, the company faces significant headwinds with expected quarterly losses of $1.35 per share (down 1400% year-over-year) and revenues projected to decline 5% to $67.18 million. With no recent changes in earnings estimate revisions and a Zacks Rank #3 (Hold) rating, analysts question whether the recent rally can sustain.

GlobeNewswire Inc.

Hydrafacial Introduces HydraClear™ Treatment Booster to Clarify Blemish-Prone Skin

SkinHealth Systems announced the launch of HydraClear Treatment Booster, a triple-acid formula designed to clarify and balance blemish-prone skin. Clinical trials showed a 38% mean reduction in total blemishes after four treatments, with 81% of participants showing fewer visible blemishes. The product will be integrated into Deluxe and Platinum Hydrafacial treatments.

GlobeNewswire Inc.

SkinHealth Systems bringt das SkinStylus® SteriLock® MicroSystem auf den europäischen Markt

SkinHealth Systems (Nasdaq: SKIN) announced the European launch of SkinStylus® SteriLock® MicroSystem, a professional micro- and nano-needling device, now available in the UK, Ireland, Germany, France, Spain, and Portugal. The expansion leverages the company's established Hydrafacial distribution network and aims to offer complementary aesthetic solutions to practitioners across the region.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 14, 20261-for-20reverse split